14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      2519. A Multi-national Phase 3, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia

      abstract

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are associated with high mortality rates. In these patients, there is an unmet need for effective antimicrobial therapy. This study enrolled participants mainly from China to support the regional use of imipenem/cilastatin/relebactam (IMI/REL). The aim of the study was to assess the efficacy and safety of IMI/REL compared with piperacillin/tazobactam (PIP/TAZ) for the treatment of HABP/VABP.

          Methods

          This study was a Phase 3, randomized trial conducted in 8 countries (NCT03583333). Participants 18–90 years of age with HABP/VABP requiring intravenous (IV) antibiotic treatment were randomized 1:1 to receive either IV IMI/REL (500 mg IMI/250 mg REL) or PIP/TAZ (4000 mg/500 mg) administered every 6 h for 7–14 days. The primary endpoint was day 28 all-cause mortality in the modified intent-to-treat (MITT) population (excluding patients with only gram-positive cocci at baseline). Secondary endpoints included clinical response rate, microbiological response rate and adverse events (AEs).

          Results

          In total, 270 patients (IMI/REL, N=134; PIP/TAZ, N=136) were included in the MITT population, with 201 patients from mainland China (IMI/REL, N=106; PIP/TAZ, N=100). Demographics and baseline characteristics were generally comparable for both treatment groups in the MITT population, with the exception of preexisting cerebrovascular conditions which were higher in IMI/REL vs PIP/TAZ group. The median age (range) was 60.0 (19–87) years and 73.3% were male (Table 1). In the MITT population, IMI/REL was non-inferior to PIP/TAZ for day 28 all-cause mortality (11.2% vs 5.9%; adjusted difference [95%CI]: 5.2% [-1.5%, 12.4%],P< 0.024). Results for key secondary endpoints were comparable between treatment groups (Table 2). Overall, the incidence of AEs was comparable between IMI/REL vs PIP/TAZ (Table 3).

          Conclusion

          In a patient population mainly from China, IMI/REL was non-inferior to PIP/TAZ for the treatment of HABP/VABP assessed by the endpoint of day 28 all-cause mortality and was associated with favorable outcomes regarding clinical and microbiological response.IMI/REL was well tolerated and had a safety profile comparable to PIP/TAZ.

          Disclosures

          Maria C. Losada, BA, Merck & Co., Inc., Rahway, New Jersey, USA: Employee|Merck & Co., Inc., Rahway, New Jersey, USA: Stocks/Bonds|Merck & Co., Inc., Rahway, New Jersey, USA: Stocks/Bonds Zlatka Iamboliyska, MD, MSD China: Employee|MSD China: Stocks/Bonds Mingfen Zhu, MD, MSD China: Employee|MSD China: Stocks/Bonds Xiaodan Guo, MD, MSD China: Employee|MSD China: Stocks/Bonds Xiaoling Du, n/a, MSD China: Employee|MSD China: Stocks/Bonds Chang Chen, MD, MSD China: Employee|MSD China: Stocks/Bonds Luke Francis Chen, MD, Merck & Co., Inc., Rahway, New Jersey, USA: Employee|Merck & Co., Inc., Rahway, New Jersey, USA: Stocks/Bonds

          Related collections

          Author and article information

          Contributors
          Journal
          Open Forum Infect Dis
          Open Forum Infect Dis
          ofid
          Open Forum Infectious Diseases
          Oxford University Press (US )
          2328-8957
          December 2023
          27 November 2023
          27 November 2023
          : 10
          : Suppl 2 , IDWeek 2023 Abstracts
          : ofad500.2137
          Affiliations
          Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai, China; Institute of Respiratory Diseases, Shanghai Jiaotong University School of Medicine , Shanghai, China;, N/A, Shanghai, China
          The First People’s Hospital of Nanning , Nanning, China, Nanning, Guangxi, China
          Changsha Central Hospital , China, Changsha, Hunan, China
          Shiyan Renmin Hospital , Shiyan, China, Shiyan, Hubei, China
          The Affiliated Huai'an First Hospital of Nanjing Medical University , Huai'an, China, Huaian, Jiangsu, China
          Merck & Co., Inc. , Rahway, New Jersey
          Merck & Co., Inc. , Rahway, New Jersey, USA, South San Francisco CA, California
          MSD, China, Xuhui district, Shanghai, China
          MSD, China, Xuhui district, Shanghai, China
          MSD, China, Xuhui district, Shanghai, China
          MSD, China, Xuhui district, Shanghai, China
          Merck & Co., Inc. , Rahway, New Jersey, USA, South San Francisco CA, California
          Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai, China; Institute of Respiratory Diseases, Shanghai Jiaotong University School of Medicine , Shanghai, China, N/A, Shanghai, China
          Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai, China; Institute of Respiratory Diseases, Shanghai Jiaotong University School of Medicine , Shanghai, China, N/A, Shanghai, China
          Author notes

          Session: 240. New Antimicrobial Drug Development

          Saturday, October 14, 2023: 12:15 PM

          Article
          ofad500.2137
          10.1093/ofid/ofad500.2137
          10678407
          36d8ad02-c2d8-4d1f-9a8a-cbf6b6db4e86
          © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

          This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

          History
          Categories
          Abstract
          AcademicSubjects/MED00290

          Comments

          Comment on this article